Physician profile
Jennifer E Moore
NPI 1053015255
$1,468.40
in general payments reported to CMS, 2019-2025
19 companies · $594 in 2025
The $594 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $355 · 2024: $519 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $296.48 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $232.89 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $172.96 | 2023-2025 | |
| Novo Nordisk INC | $152.75 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.84 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $109.61 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $68.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $59.72 | 2023-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $42.46 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $42.08 | 2023-2024 | Rexulti, Nuedexta |
| Mayne Pharma Commercial LLC | $29.14 | 2023 | |
| Ani Pharmaceuticals, INC. | $22.29 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $21.64 | 2024 | Veozah |
| Bard Peripheral Vascular, INC. | $21.03 | 2025 | Venclose Maven Catheter |
| Seqirus USA INC | $19.42 | 2025 | Flucelvax, Fluad |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $17.82 | 2025 | Omnipod |
| Shield Therapeutics INC | $15.89 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.56 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.73 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.